(Q43034369)

English

Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment

scientific article published on 8 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

genetic variation

1 reference

based on heuristic

inferred from title

Kazuaki Chayama

14

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

12 November 2017

Hiromitsu Kumada

16

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

12 November 2017

Fumitaka Suzuki

2

object named as

Fumitaka Suzuki

1 reference

Europe PubMed Central

12 November 2017

13

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

12 November 2017

Masahiro Kobayashi

9

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

12 November 2017

Yoshiyuki Suzuki

7

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

12 November 2017

1

object named as

Norio Akuta

1 reference

Europe PubMed Central

12 November 2017

12

object named as

Yasuji Arase

1 reference

Europe PubMed Central

12 November 2017

6

object named as

Hitomi Sezaki

1 reference

Europe PubMed Central

12 November 2017

11

object named as

Satoshi Saitoh

1 reference

Europe PubMed Central

12 November 2017

Yusuke Kawamura

4

object named as

Yusuke Kawamura

1 reference

Europe PubMed Central

12 November 2017

Mariko Kobayashi

10

object named as

Mariko Kobayashi

1 reference

Europe PubMed Central

12 November 2017

8

object named as

Tetsuya Hosaka

1 reference

Europe PubMed Central

12 November 2017

author name string

Miharu Hirakawa

3

1 reference

Europe PubMed Central

12 November 2017

Hiromi Yatsuji

5

1 reference

Europe PubMed Central

12 November 2017

Yusuke Nakamura

15

1 reference

Europe PubMed Central

12 November 2017

publication date

8 June 2012

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

55

1 reference

Europe PubMed Central

12 November 2017

6

1 reference

Europe PubMed Central

12 November 2017

417-425

1 reference

Europe PubMed Central

12 November 2017

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

A high-throughput SNP typing system for genome-wide association studies

1 reference

https://api.crossref.org/works/10.1159%2F000323526

21 January 2018

Identifiers

10.1159/000323526

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43034369&oldid=2139235474"